Gossamer Bio, Inc. (GOSS)

Nasdaq: GOSS · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2018

Full chart Alerts Compare

Grade4.0

◀ Past 3.2● Present 4.6▶ Future 4.0

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$48.5M-57.7%

Net income-$170M-201.4%

Earnings per share$-0.75-200.0%

Operating cash flow-$171M-4838.5%

Cash$37.7M-18.1%

Debtn/a

Shareholders’ equity-$123M-516.2%

Shares, diluted228.5M+1.0%

Return on equityn/a

The recordfrom its filings

Filings in 202691

Newest filingNov 10 · 8-K

Annual reportMar 17, 2026

Quarterly reportNov 10, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted0

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $78.4MNet income -$125MCash from operations -$156Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 29, 2026 · SEC EDGAR · Form SCHEDULE 13D/A

Activist holder update, amended

Open the filing on sec.gov

Oct 28, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 8, 2026 · SEC EDGAR · Form SCHEDULE 13D/A

Activist holder update, amended

Open the filing on sec.gov

Sep 28, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Sep 28, 2026 · SEC EDGAR · Form SCHEDULE 13D/A

Activist holder update, amended

Open the filing on sec.gov

Sep 25, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Gossamer Bio, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in San Diego, CA.

Newest on the record

Current report on Nov 10. Before it, quarterly report on Nov 10.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About GOSS

Gossamer Bio, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in San Diego, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $48 million and a loss of $170 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersSan Diego, CA

Business modelProduct business

ExchangeNasdaq

Filing since2018

Fiscal year endsDec 31

SEC number (CIK)1728117

Peers on fileGYRE, AQST, LXRX, FBIO

Who runs it

Financial performance

In fiscal 2025 Gossamer Bio’s revenue was $48.47 million, down 57.7% from $114.7 million the year before. It made a net loss of $170.4 million.

Annual report, filed Mar 17, 2026.

Financial statements

The grade

Gossamer Bio grades 4.0 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past3.2

● Present4.6

▶ Future4.0

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton GOSS · research, not advice